The pharmaceutical industry faces a period of seismic change, with much of the movement and play taking place in Asia. AstraZeneca’s recent performance and strategic moves paint a vivid picture of this trend. The company’s annual revenues exploded by an extraordinary 21%, soaring to £43 billion ($54.1 billion). This rapid growth, mainly fueled by sales of the company’s oncology, respiratory and immunology treatments, was enough to get OverTraders.com buzzing. Stocks jumped 4.6% pre-market, showing the financial bullishness coming from this development. This trend reflects the growing importance of the Asian market for international pharma majors.
The road hasn’t been an easy one. AstraZeneca Chinese operations president Leon Wang Lehua and some other current and former employees have recently been detained. To mention just a few, GM Health are facing grave accusations of insurance fraud, data breaches, and importing unlicensed medicines to the region, marking the perilous landscape of conducting business in this intricate territory. Many of these challenges notwithstanding, the investment landscape is changing. Today, we’re witnessing a tremendous pivot towards Asia that will define decades to come.
Accelerating Research for Enhanced Patient Outcomes
The soul of any pharmaceutical enterprise resides in the purported R&D endeavors. AstraZeneca knows this—for them innovation isn’t a buzzword but a belief in foundational theory application. The company focuses on oncology, respiratory, and immunology therapies. This shift is a smart strategic move, given the rapidly growing healthcare needs of the country’s booming Asian population.
Importance of Innovative Approaches
Innovation is not only about creating new compounds, it is creating a better way to receive care. This reimagination includes the areas of personalized medicine, digital health solutions, and novel drug delivery systems. By embracing these innovative approaches, AstraZeneca can tailor its treatments to the specific needs of Asian patients, leading to better outcomes and improved quality of life.
Strategies for Effective Research Collaboration
We know that collaboration is the only way to accelerate the pace of this research. Through R&D AstraZeneca can nurture alliances with neighbouring universities, research institutes and even other pharma players to tap into their additional skills and capabilities. This unusual collaborative approach speeds drug development and reduces costs. Beyond that, it continues to broaden our perspective on the nuanced and complex healthcare challenges taking place all across Asia.
Impact of COVID-19 on Healthcare Transformation
The COVID-19 outbreak has been a major impetus for change across all industries especially in the healthcare sector, including Asia. However, at the same time, it has shown weaknesses of our current healthcare infrastructure and fast-tracked the use of digital solutions.
Changes in Healthcare Delivery
The pandemic has accelerated the use of telehealth, remote patient monitoring, and online pharmacies. All of these advances have made healthcare easier and more convenient to access, especially for patients in rural or isolated areas. AstraZeneca stands to benefit from these trends if the company is able to build digital health solutions that enhance its current drug pipeline.
Lessons Learned from the Pandemic
Through our partners and programs, the pandemic has proven the need for all-hazards preparedness, community resilience and strong collaboration. Pharmaceutical companies should be prepared to respond quickly in future public health emergencies. They can do this through investing in R&D, reinforcing critical supply chains, and working hand-in-hand with governments and healthcare providers.
Understanding the Complexity of the APAC Region
As region, the Asia Pacific (APAC) is both big and complex. It’s the largest collection of developed and developing economies, with very different healthcare systems, languages, cultures, political realms and technology readiness. While this complexity is a challenge for the sponsors, it’s an opportunity.
Diverse Healthcare Systems
Each country within the APAC region features a distinct and unique healthcare system. They are worlds apart in government funding, private insurance coverage, and access to care. Pharmaceutical companies need to be aware of these differences and adjust their market access strategies accordingly.
Cultural Considerations in Pharma
Cultural factors, for their part, can be incredibly influential when it comes to healthcare decision-making. Take traditional medicine, for instance, which continues to be widely practiced in much of Asia. Pharmaceutical companies need to be aware of such cultural differences and create culturally sensitive marketing and communications campaigns.
Challenges Facing the Pharmaceutical Industry in APAC
As lucrative as the APAC market certainly is, there are many challenges for pharmaceutical companies.
Regulatory Hurdles
As noted by GAMP South Asia founder Wakeham, the APAC regulatory landscape presents a challenge. Local knowledge Regulatory agencies throughout the region display a distinct lack of knowledge and expertise. Navigating these regulatory hurdles can be arduous and costly.
Market Access Issues
They may find gaining market access in APAC difficult with pricing pressures and reimbursement policies limiting access alongside the competition phase of a generic drug. The pressure is on pharmaceutical companies to create innovative, more agile market access strategies to make sure their products get into the hands of patients who need them.
Ensuring Quality and Compliance in Pharma
Without a doubt, quality and compliance are top priorities for the pharmaceutical industry. Past precedent — pharmaceutical companies are required to adhere to rigorous quality standards. They need to pass through the regulatory gauntlet to ensure safety and effectiveness of their products.
Importance of Harmonization
Harmonization of regulatory standards across APAC would be beneficial in standardizing the drug development and registration process. This is not to say that efforts are not already behind regulatory requirements harmonization in the region, there is simply still further work to be done.
Alignment with PIC/s GMP Standards
To ensure the integrity of the process, pharmaceutical companies need to adhere to the PIC/S GMP guidelines. This alignment would be key for actually exporting successfully to those global markets. Noticeably absent from PIC/S membership are regulatory authorities in India and China. There are millions of export manufacturers, in both countries, tightly regulated to PIC/S GMP standards to access global markets. Moreover, China recently submitted its application to join PIC/S.
Variability in Regulatory Expertise Across APAC
Additionally, Wakeham shares that knowledge and expertise among regulatory agencies is different across the region. Through his intensive, hands-on training, he’s empowered dozens of these agencies to improve their culture and practice capabilities.
Differences in Regulatory Frameworks
The APAC regulatory landscapes differ widely from one country to the next. This can lead to significant hurdles for pharmaceutical manufacturers wishing to register and commercialize their goods within the region.
Need for Training and Development
Regulatory professionals in APAC are in high demand, but they require constant and up-to-date training and development. This will deepen their understanding and experience tremendously. This would go a long way toward ensuring that regulatory decisions are based on the best available science and practices.
The Future of Digitalization in Pharma
Digitalization is disrupting everyone’s business models. The pharmaceutical industry is going through a massive transition brought on by digitalization. Harsh Gandhi will be AstraZeneca’s new Chief Information & Digital Officer. His appointment, the first in more than 20 years, shines a spotlight on digital transformation’s key role.
Emerging Technologies
Technologies like artificial intelligence (AI), machine learning (ML), and blockchain are already transforming the pharmaceutical landscape. The truth is, AI and ML hold tremendous potential to accelerate drug discovery, personalize treatments and improve patient outcomes. Blockchain is a tool to improve supply chain security and counterfeiting measures.
Benefits of Digital Transformation
A successful digital transformation will yield greater operational efficiency and cost-effectiveness—all while enhancing the level of patient care and outcomes. With an ever-growing digital-first customer base, the pharmaceutical industry has much to gain by championing the disruptive opportunities that digital technologies have introduced.
Country-Specific Insights
Recognising that one size doesn’t fit all, and the unique qualities of each country in APAC will determine your success.
Thailand
Thailand’s dynamic biopharmaceutical industry can be partly attributed to the comparatively large size of its domestic market.
The ISPE Thailand Affiliate
The ISPE Thailand Affiliate continues to offer this much-needed venue for pharmaceutical-focused professionals to engage and learn from one another, while collectively pushing the industry forward.
Indonesia
With a population of more than 270 million people, Indonesia is a potentially lucrative market for new and improved innovative drugs.
The ISPE Indonesia Affiliate
This newest ISPE Indonesia Affiliate will provide pharmaceutical industry professionals in Indonesia with education, training, and networking opportunities.
India - The Pharmacy of the World
The Indian pharmaceutical industry is now a truly global powerhouse, having reached incredible heights not only in the APAC region but worldwide. In 2022, Indian companies convincingly won almost 50% of the 742 abbreviated new drug application approvals awarded by the US FDA.
Singapore
Complementing this is a deep investment in biologics and other complex, high-value products including personalized medicines. In response, it has become a major center for pharmaceutical production in the region.
The ISPE Singapore Affiliate
The ISPE Singapore Affiliate has been a leader in bringing the industry together for collaboration and innovation in the pharmaceutical industry in Singapore.
Malaysia
Malaysia is an increasingly important market for pharmaceutical companies.
The ISPE Malaysia Affiliate
The ISPE Malaysia Affiliate is dedicated to the advancement of pharmaceutical manufacturing science and regulation for the benefit of global public health.
Philippines
The ISPE Philippines Affiliate
The ISPE Philippines Affiliate is a great resource to support the growth and development of the pharmaceutical professionals in the Philippines.
Vietnam
Australia and New Zealand
Japan
Japan is the third-largest pharmaceutical market in the world.
Conclusion
AstraZeneca’s experience in Asia provides a good sense of the current state and direction of the industry. The region's growing middle class, aging population, and increasing healthcare spending are driving demand for innovative medicines and healthcare solutions. Although challenges still lie ahead, the potential is huge. Incentivize innovation, collaboration and creativity to help address the specific needs of each country. In doing so, pharma can maximize Asian market possibilities and more significantly enhance millions of patients’ lives.
Unlocking Access to Member-Only Content
Become a member of OverTraders.com today to get exclusive analysis and commentary on the pharmaceutical industry. Find great ideas to invest in, and become a more informed advocate!
